News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
283,608 Results
Type
Article (14923)
Company Profile (299)
Press Release (268380)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (80258)
Career Advice (163)
Deals (13418)
Drug Delivery (39)
Drug Development (50909)
Employer Resources (31)
FDA (5915)
Job Trends (5252)
News (145913)
Policy (10151)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (945)
Accelerated approval (20)
Adcomms (14)
Allergies (82)
Alliances (21867)
ALS (125)
Alzheimer's disease (1034)
Antibody-drug conjugate (ADC) (241)
Approvals (6120)
Artificial intelligence (264)
Autoimmune disease (116)
Automation (11)
Bankruptcy (106)
Best Places to Work (4654)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (367)
Cancer (3169)
Cardiovascular disease (242)
Career advice (148)
Career pathing (7)
CAR-T (219)
CDC (5)
Cell therapy (565)
Cervical cancer (15)
Clinical research (43917)
Collaboration (1161)
Company closure (2)
Compensation (608)
Complete response letters (40)
COVID-19 (1116)
CRISPR (86)
C-suite (558)
Cystic fibrosis (113)
Data (4392)
Denatured (15)
Depression (92)
Diabetes (258)
Diagnostics (1473)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (190)
Drug pricing (49)
Drug shortages (3)
Duchenne muscular dystrophy (216)
Earnings (31919)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (52007)
Executive appointments (626)
FDA (7711)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (990)
Gene editing (182)
Generative AI (22)
Gene therapy (490)
GLP-1 (506)
Government (1156)
Grass and pollen (3)
Guidances (176)
Healthcare (6687)
HIV (18)
Huntington's disease (43)
IgA nephropathy (76)
Immunology and inflammation (190)
Immuno-oncology (40)
Indications (67)
Infectious disease (1222)
Inflammatory bowel disease (157)
Inflation Reduction Act (10)
Influenza (39)
Intellectual property (168)
Interviews (18)
IPO (7394)
IRA (12)
Job creations (869)
Job search strategy (130)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1414)
Liver cancer (41)
Longevity (11)
Lung cancer (424)
Lymphoma (249)
Machine learning (24)
Management (7)
Manufacturing (383)
MASH (131)
Medical device (2688)
Medtech (2698)
Mergers & acquisitions (6657)
Metabolic disorders (731)
Multiple sclerosis (111)
NASH (13)
Neurodegenerative disease (231)
Neuropsychiatric disorders (70)
Neuroscience (1965)
Neurotech (1)
NextGen: Class of 2026 (2044)
Non-profit (886)
Now hiring (30)
Obesity (331)
Opinion (125)
Ovarian cancer (131)
Pain (103)
Pancreatic cancer (164)
Parkinson's disease (234)
Partnered (12)
Patents (302)
Patient recruitment (333)
Peanut (44)
People (26772)
Pharmaceutical (44)
Pharmacy benefit managers (7)
Phase 1 (15499)
Phase 2 (20349)
Phase 3 (12976)
Pipeline (3326)
Policy (90)
Postmarket research (877)
Preclinical (6539)
Press Release (30)
Prostate cancer (146)
Psychedelics (50)
Radiopharmaceuticals (239)
Rare diseases (656)
Real estate (1457)
Recruiting (12)
Regulatory (9999)
Reports (19)
Research institute (973)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (183)
Series B (136)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (120)
Sponsored (15)
Startups (2008)
State (1)
Stomach cancer (5)
Supply chain (35)
Tariffs (18)
The Weekly (62)
Vaccines (337)
Venture capital (69)
Weight loss (174)
Women's health (26)
Worklife (2)
Date
Today (54)
Last 7 days (329)
Last 30 days (1183)
Last 365 days (18147)
2026 (1734)
2025 (18388)
2024 (20717)
2023 (22605)
2022 (26965)
2021 (27959)
2020 (23507)
2019 (16399)
2018 (11856)
2017 (13837)
2016 (11882)
2015 (14400)
2014 (10447)
2013 (7515)
2012 (7568)
2011 (7632)
2010 (7474)
Location
Africa (156)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18319)
Australia (3111)
California (7111)
Canada (1853)
China (777)
Colorado (247)
Connecticut (258)
Delaware (235)
Europe (39627)
Florida (904)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (399)
India (35)
Indiana (167)
Iowa (8)
Japan (226)
Kansas (83)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (765)
Massachusetts (5656)
Michigan (110)
Minnesota (248)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1712)
New Mexico (13)
New York (1767)
North Carolina (830)
North Dakota (6)
Northern California (3502)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1285)
Puerto Rico (9)
Rhode Island (25)
South America (217)
South Carolina (9)
Southern California (2814)
Tennessee (41)
Texas (917)
United States (23591)
Utah (103)
Virginia (136)
Washington D.C. (38)
Washington State (593)
West Virginia (1)
Wisconsin (45)
283,608 Results for "mediar therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Alloy Accelerates Mediar Timeline to the Clinic for Complex Fibrosis Targets
February 3, 2026
·
3 min read
Press Releases
Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class Fibrosis Portfolio
January 7, 2026
·
5 min read
Collaboration
Lilly Makes $780M+ IPF Play with Mediar Partnership
Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early studies have found to be safe and capable of engaging its target.
January 10, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Mediar Therapeutics Doses First Patient in Phase 2 WISPer Trial of MTX-463 for Idiopathic Pulmonary Fibrosis
June 5, 2025
·
3 min read
Press Releases
Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
January 13, 2025
·
4 min read
Drug Development
Mediar Advances First-in-Class Fibrosis Portfolio to the Clinic with First Cohort Dosing in Phase 1 trial of MTX-463 and Establishes Clinical Advisory Board
Mediar Therapeutics, Inc. announced that, following FDA clearance of its investigational new drug application, the first cohort of participants has been dosed in a Phase 1 trial evaluating the safety and tolerability of MTX-463.
May 6, 2024
·
4 min read
Genetown
Mediar Therapeutics Announces Clinical Candidates for Lead Fibrosis Programs, Strategic Collaborations and Key Leadership Addition
Mediar Therapeutics Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt fibrosis progression, today announced several milestones that support clinical advancement of its portfolio of novel antibodies.
October 25, 2023
·
4 min read
Press Releases
Mediar Therapeutics Initiates Second Clinical Program in Portfolio of Novel First-In-Class Antibodies Designed to Halt Fibrosis
August 7, 2024
·
3 min read
Business
Novartis and Pfizer-Backed Mediar Nets $85M for Fibrosis Paradigm Shift
Mediar Therapeutics added another $85 million to its coffers Wednesday to take its first-in-class fibrosis therapies to clinic.
March 15, 2023
·
2 min read
·
Kate Goodwin
Genetown
Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies
Mediar Therapeutics Inc. announced a $105M financing, including a recent $85 million Series A round co-led by Novartis Venture Fund and Sofinnova Partners and with participation from Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol Myers Squibb, Eli Lilly & Company, Ono Venture Investment and Mass General Brigham Ventures.
March 15, 2023
·
4 min read
1 of 28,361
Next
